Articles tagged with Drug Studies
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
Scientists found that a small increase in temperature can drastically change mutation frequency in E. coli bacteria, facilitating resistance development. The results suggest using fever control or antimicrobial drugs at higher temperatures to mitigate antibiotic resistance.
A study found that neural balance, measured by the E/I ratio, is associated with brain maturity and better cognitive ability. Research suggests that as children develop, their E/I ratios decrease, leading to improved performance in cognitive tests.
Researchers developed microscopic robots that swim through lungs to deliver cancer-fighting medication directly to metastatic tumors. The approach inhibited tumor growth and spread, improving survival rates compared to control treatments.
This review bridges traditional wisdom and modern science to examine the safety, efficacy, and bioactivity of herbal medicines. It highlights successful case studies where herbal remedies enhance patient outcomes when used alongside conventional treatments.
The fungus secretes enzymes that transform tea chemical components through oxidation, degradation, and condensation reactions. This results in high-quality fermented teas with enhanced flavor and health benefits.
Coptis teeta Wall. has been traditionally used to treat malaria, stomach ache, diarrhea, skin conditions, eye disorders, and gastrointestinal issues. The plant's compounds have shown antibacterial activity, anti-inflammatory effects, and potential in treating chronic conditions like diabetes and cancer.
A clinical trial shows that a combination of injectable naltrexone and extended-release oral bupropion reduces methamphetamine use for up to 12 weeks. The study found a significant increase in methamphetamine-negative urine tests among participants receiving the two-drug therapy.
A new study published in the New England Journal of Medicine found that crinecerfont reduces adrenal androgen production by half in adults with Congenital Adrenal Hyperplasia (CAH), allowing for lower doses of corticosteroids. This could lead to fewer long-term side effects associated with high-dose corticosteroid use.
The number of calls to US poison centers has increased sharply, with a 233.9% rise in intentional exposures among adults. The severity of unintentional exposures also increased, with 37.4% more cases resulting in severe harm and 65.3% more deaths.
The NIH is investing $30 million in a pilot program called CARE for Health, which aims to integrate clinical research with community-based primary care. The initiative seeks to improve health outcomes by providing access to clinical research and expanding opportunities for participation in clinical trials.
A systematic review and meta-analysis of over 20,000 patients found that one in six to seven patients will experience discontinuation symptoms directly caused by stopping the medication. Severe symptoms occurred in about 3% of patients, with certain antidepressants increasing the risk.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
A clinical trial discovered that the drug abrocitinib, approved for eczema treatment, significantly reduced symptoms of patients with severe itching diseases. Abrocitinib improved symptoms in both prurigo nodularis and chronic pruritus of unknown origin by 78% and 54%, respectively.
A meta-analysis of 15 randomized studies found that patients taking GLP-1 medications experienced only mild differences in gastric emptying, delaying solid food by about 36 minutes. The findings suggest it may be safe to continue these medications before surgery without a high risk of aspiration.
The first phase 1 trial of the bispecific antibody FS222 demonstrates promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy. Preliminary results show partial or complete objective response rates in various tumor types.
A study led by Washington State University scientists found that inhibiting CDK7 could help prevent heart damage associated with doxorubicin, a commonly used cancer chemotherapy medication. The researchers also discovered that CDK7 inhibition enhances the medication's cancer-killing capability.
A study from Michigan Medicine reveals a connection between neutrophil activation and severe cytokine release syndrome (CRS), a potentially life-threatening reaction to CAR T-Cell therapy. Researchers identified biomarkers of NETosis, a process in which neutrophils create webs that may contribute to CRS.
A new study by ECOG-ACRIN Cancer Research Group aimed to address disparities in breast cancer care for Black patients. The trial found that tailoring research to the needs of underserved groups is effective, with docetaxel showing lower rates of peripheral neuropathy and dose reductions compared to paclitaxel.
The phase 2 clinical trial of BXCL701 in combination with pembrolizumab showed a 50% progression-free survival rate and significant reductions in CA19-9 markers, indicating potential anti-cancer effects. The treatment has also shown low blood pressure as the main side effect.
A recent study has identified over 300 distinct types of bacteria in Roman Baths water, including those with antibiotic-producing capabilities. These microorganisms show promise as a potential source of novel natural products to combat antibiotic resistance.
Wake Forest University School of Medicine has received a $1.5 million grant to study bone microarchitecture in patients following bariatric surgery. The researchers will use high-resolution peripheral quantitative computed tomography (HR-pQCT) imaging to assess bone loss and muscle changes after weight-loss surgery.
A clinical trial led by Mount Sinai researchers shows zodasiran, an RNA inhibitor targeting ANGPTL3, significantly reduces various types of cholesterol and triglycerides. The therapy also lowers apolipoprotein B, a lipid-transporting protein linked to heart disease.
A new study published in JAMA suggests that kidneys from deceased donors on dialysis can be safely transplanted into recipients, reducing the pool of available donors. The study found no significant difference in transplant failure or death rates between recipients of kidneys from donors with and without dialysis.
Quadruple therapies offer deeper responses and longer clinical benefits for patients with newly diagnosed multiple myeloma. The addition of an immunotherapy agent to the backbone of small molecule drugs may improve overall survival and reduce the need for bone marrow transplants.
Researchers have developed a novel solubilizer for olaparib, a selective PARP inhibitor, using π-π-stacked poly (ɛ-caprolactone)-based micelles. The studies found that these micelles improved the solubility of olaparib and exhibited sustained release behavior in vitro.
A new study found that nearly 3% of healthy adolescents aged 11-15 have used commercial CBD products for medicinal or health-related reasons. The study identified predictors of commercial CBD use, including older age, certain health conditions, and parental attitudes towards cannabis use.
Certain combinations of medication or psychotherapy with transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) are supported by clinical studies for major depressive disorder (MDD) treatment. Researchers recommend more sophisticated trial designs to move the field forward.
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
Researchers report that dupilumab substantially decreases exacerbation frequency and improves lung function as well as symptom burden in COPD patients with type 2 inflammation. The study's findings are promising for these patients, who have a high risk of exacerbations.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
Researchers at Ochsner Health have developed SRP-001, a novel medication that leverages unique biological mechanisms to alleviate pain without typical side effects. The first-in-human Phase 1 trial confirms SRP-001's safety and tolerability, paving the way for its progression to further clinical stages.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
Researchers found a significant disparity between the placebo group and those receiving varenicline, with a quit rate of 45% compared to 30% in the placebo group. The study suggests that varenicline may be effective in helping adults quit using e-cigarettes.
A review of clinical studies suggests that combining TMS or tDCS with certain types of psychotherapy or medication can lead to greater symptom reduction in patients with major depressive disorder. However, the research has limitations and more sophisticated trial designs are needed to move the field forward.
Researchers have developed a new weight loss drug that combines GLP-1 with molecules blocking the NMDA receptor, exploiting its effects on appetite control and neuroplasticity. This approach shows promise for greater weight loss in mice than existing medications.
Insilico Medicine's lead compound demonstrates strong enzymatic activity, selectivity, and favorable ADME properties, as well as antitumor activity in various animal models. The company's generative AI-powered platform generated over 3,600 candidate molecules before identifying the promising lead compound.
Scientists have recruited over 20,000 volunteers to a resource aimed at accelerating dementia drug development. The cohort will enable healthy individuals with increased genetic risk to participate in clinical trials, allowing researchers to test new treatments before symptoms appear.
Two studies based on the SELECT trial show semaglutide leads to sustained weight loss of 10% body weight and 7cm waist reduction after 4 years, regardless of starting weight or BMI. The medication also delivers cardiovascular benefits, with a lower risk of heart attack, stroke, or death.
Researchers at UC San Francisco found that dispensing abortion pills through the mail is a safe and effective method, with nearly 98% of patients completing their abortions. The study suggests that this model can help increase access to abortion care for clinicians and patients alike.
A new study finds mail-order pharmacy dispensing of mifepristone for medication abortion is effective, acceptable to patients, and feasible. This care model can improve access to medication abortion services and reduce the need for in-person screening.
A clinical trial found that aficamten significantly increased maximum oxygen use in patients with obstructive hypertrophic cardiomyopathy. This improvement enables patients to perform everyday tasks more easily, such as walking and household chores. Researchers believe aficamten has promise as a treatment for this condition.
A new study published in Addiction journal found that high-potency cannabis use between 16 and 18 doubles the risk of psychotic experiences from 19 to 24. Researchers analyzed data from the Children of the 90s study, which tracked over 14,000 individuals from birth to age 24.
A Danish study found that patients who tapered off semaglutide slowly and focused on lifestyle changes maintained their weight loss for at least 6 months. Lower doses of the drug were as effective as higher ones, with a tailored approach minimising side-effects.
A secondary analysis of a randomized clinical trial found that home blood pressure self-monitoring plus medication self-titration reduces BP in the longer term without increasing healthcare use or adverse events. This simple, inexpensive intervention has potential to improve long-term hypertension control in routine clinical practice.
A clinical trial found that adding Radix Salviae decoction to conventional treatment did not change coronary stenosis and restenosis rates after percutaneous coronary intervention. The diagnosis of MI/angina, average stent length, and ALT levels were associated with neostenosis occurrence.
The ECOG-ACRIN Cancer Research Group has launched the ComboMATCH-E5 trial, evaluating the combination of sotorasib and panitumumab in patients with KRAS G12C-mutated advanced solid tumors. The study aims to assess the efficacy and safety of the combination in this patient population.
A new Cochrane review suggests that taking zinc may reduce the duration of common cold symptoms by around two days, but the evidence is not conclusive. Common side-effects include bowel problems, nausea, and unpleasant taste.
A study by Duke University researchers found that combining a low-carb, high-fat keto diet with fluconazole significantly improved treatment outcomes against fungal meningitis. The keto diet increased the effectiveness of fluconazole by reducing fungal levels by up to ten thousandfold.
Astragalus polysaccharide regulates VRC metabolism by increasing Bifidobacterium bifidum abundance and reducing inflammation in the liver. This leads to improved VRC metabolism, with high-dose APS showing stronger effects.
Scientists have found an effective treatment for spitting cobra snakebites by blocking one of the major dermonecrosis-causing toxins with varespladib. The study suggests that this repurposed drug can prevent tissue damage and may become a valuable treatment against black-necked and red spitting cobra venoms.
A recent study in Saudi Arabia assessed the effectiveness of an educational program improving epilepsy care among caregivers. The intervention showed a significant decrease in knowledge gaps, with 23.2% having sufficient knowledge post-intervention compared to 60% before.
A new study by Boston University School of Public Health found that less than 15% of US college students can administer naloxone, a life-saving medication for opioid overdoses. Despite this, nearly 62% of students can identify signs of an overdose and nearly 67% feel comfortable calling emergency services.
A new study from the University of Texas MD Anderson Cancer Center found that increasing treatment plan doses or altering regimens significantly improves cessation success for persistent smokers who previously tried to quit and failed. Varenicline was more effective than combined nicotine replacement therapy in aiding smokers to quit.
Researchers found that metformin decreases the amount of COVID-19 virus in the body and lowers the chances of viral rebound. The study showed a significant reduction in long COVID cases and hospitalizations among adults treated with metformin.
Researchers at the University of Toronto have found a way to better control the preclinical generation of key neurons depleted in Parkinson's disease. They developed an efficient method for stimulating stem cell differentiation to produce neural cells in the midbrain, which closely resemble dopaminergic neurons of natural origin.
A survey of healthcare providers in the Middle East reveals a good understanding of halal pharmaceuticals, but gaps in knowledge, particularly about ingredients and aligning with Islamic principles. Personalized education and culturally sensitive care can address patient concerns and improve healthcare outcomes for all patients.
A study of 15 brand-name drugs found that competition from 'skinny label' generics saved Medicare nearly $15 billion from 2015 to 2021. The largest savings were seen for rosuvastatin, pregabalin, and imatinib, with actual spending being $16.8 billion versus projected spending of $31.5 billion.
A new study on aspirin's role in breast cancer treatment highlights critical issues related to health equity and aging, with implications for future disease intervention trials. The study found that aspirin did not decrease the risk of cancer recurrence or improve survival among breast cancer survivors.
A honey-containing nanoemulsion was developed and characterized for stability, maintaining normal pH values corresponding to skin pH throughout a 90-day testing period. The emulsion showed non-Newtonian flow and pseudo-plastic behaviour required for ideal topical formulation.